Abstract:AACR Annual Meeting-- Apr 14-18, 2007; Los Angeles, CA 1452 The Raf /MEK kinase cascade are pivotal regulators of cellular proliferation. The majority of human cancers overexpress Bcl-2, Bcl-xL and/or Mcl-1, the important negative regulators of apoptosis. Recent studies suggest that the Bcl-2 and Raf/MEK pathways together confer an aggressive, apoptosis-resistant phenotype. Sorafenib (Nexavar) is the first oral multikinase inhibitor that targets Raf/MEK and cell proliferation and angiogenesis, and is approved for treating renal cancer. However, expression of Bcl-2 or Mcl-1 could protect cells from Sorafenib induced apoptosis. AT-101 is a potent small molecule pan-Bcl-2 (Bcl-2, Bcl-xL and Mcl-1) inhibitor currently in Phase II clinical trials. In this study we investigated whether the simultaneous inhibition of Bcl-2 by AT-101 and Raf/MEK function by Sorafenib could result in enhanced antitumor activity. Methods: Cell growth inhibition was measured using WST-based assays. The CalcuSyn program was used to assess drug interaction by calculating the Combination Index (CI) value. In vivo , the ability of AT-101 to potentiate the anticancer effect of Sorafenib in xenograft models was evaluated. Summary: Three cell lines, breast cancer MDA-231, NSCLC H460 and A549, with overexpression of Bcl-2, Bcl-xL and Mcl-1 proteins, were treated with Sorafenib and AT-101 as a single agent and in combination. Sorafenib inhibited the growth of three cell lines with IC50 at 3-8 uM, whereas AT-101 inhibited the growth with IC50 at 3-6 uM. When treating cells simultaneously with both agents, AT-101 demonstrated strong synergy with Sorafenib in A549 (CI value=0.38, average of the CI values obtained at the ED50, ED75 and ED90), H460 (CI values avg.=0.67), and MDA-231 (CI values avg.=0.72). In the MDA-231 xenograft model, AT-101 demonstrated dose-dependent anti-tumor activity. At a dose of 7.5 mg/kg (p.o., qd x 28 days), AT-101 alone resulted in limited tumor growth inhibition (T/C=69%), and at a dose of 30 mg/kg, AT-101 caused tumor growth inhibition with a T/C=33%. However, the combination effect of both compounds was more than additive, resulting in a T/C of 8%, as compared to Sorafenib alone (20mg/kg, p.o, qd x 18 days, T/C=18%) (P<0.0001). In the same model, a combination of high dose AT-101 with a lower dose of Sorafenib (7.5 mg/kg) was also more effective than either agent alone (T/C value of 17%, versus T/C=33% for AT-101 and 30 % for Sorafenib, respectively) (P=0.0026). Combination therapy also achieved significant tumor growth delay (T-C = 35 or 46 days) as compared with either agent alone.Further studies with combination therapy in NSCLC models are currently underway. Conclusion: In summary, these data suggest that targeting both cell survival and cell growth pathways may offer significant synergy over targeting cell growth signaling alone.

Sorafenib, a multi-target inhibitor, and OSU-03012, a phosphoinositide- dependent kinase-1 inhibitor, are synergistic in cytotoxicity against nasopharyngeal carcinoma cells

Inhibition of the Wnt/β-catenin Signaling Pathway Improves the Anti-Tumor Effects of Sorafenib Against Hepatocellular Carcinoma.

Improved Antitumor Effect Of Combining Wnt/Beta-Catenin Inhibition With Sorafenib In Hepatocellular Carcinoma

Sorafenib with ASC-J9® Synergistically Suppresses the HCC Progression Via Altering the Pstat3-Ccl2/bcl2 Signals.

Abstract A155: Activation of PI3K/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells

Synergistic activity of sorafenib and betulinic acid against clonogenic activity of non‐small cell lung cancer cells

Synergistic Effect of AT-101, an Orally Active Pan Bcl-2 Family Proteins Inhibitor in Combination with Dual-Raf/mek and VEGFR Kinase Inhibitor Sorafenib (Nexavar)

Abstract 2052: WNT/beta-catenin signaling inhibitors improve the anti-proliferative effect of sorafenib against hepatocellular carcinoma (HCC) cells.

Sorafenib Enhances the Chemotherapeutic Efficacy of S-1 Against Hepatocellular Carcinoma Through Downregulation of Transcription Factor E2F-1

Down-regulation of Myeloid Cell Leukemia-1 through Inhibiting Erk/Pin 1 Pathway by Sorafenib Facilitates Chemosensitization in Breast Cancer

Inhibition of Neddylation Modification by MLN4924 Sensitizes Hepatocellular Carcinoma Cells to Sorafenib

Ursolic acid enhances the antitumor effects of sorafenib associated with Mcl-1-related apoptosis and SLC7A11-dependent ferroptosis in human cancer

MCL1 inhibition: a promising approach to augment the efficacy of sorafenib in NSCLC through ferroptosis induction

A combination of sorafenib and SC-43 is a synergistic SHP-1 agonist duo to advance hepatocellular carcinoma therapy

Sorafenib May Enhance Antitumour Efficacy in Hepatocellular Carcinoma Patients by Modulating the Proportions and Functions of Natural Killer Cells.

Synergistic Growth Inhibition by Sorafenib and Cisplatin in Human Osteosarcoma Cells

WEE Family Kinase Inhibitors Combined with Sorafenib Can Selectively Inhibit HCC Cell Proliferation

Inhibition of cyclin E1 sensitizes hepatocellular carcinoma cells to regorafenib by mcl-1 suppression

Suppression of the expression of multidrug resistance protein in liver cancer cells by sorafenib and the growth of subcutaneous tumor in nude mice model treated by a combination of sorafenib and fluorouracil

Combinatorial immunotherapy of sorafenib and blockade of programmed death-ligand 1 induces effective natural killer cell responses against hepatocellular carcinoma

Gemcitabine and APG-1252, a novel small molecule inhibitor of BCL-2/BCL-XL, display a synergistic antitumor effect in nasopharyngeal carcinoma through the JAK-2/STAT3/MCL-1 signaling pathway